DevCo's lexipafant renaissance
Nearly a year to the day that British Biotech plc announced that it was dropping Zacutex lexipafant as a potential treatment for acute pancreatitis, DevCo Pharmaceuticals Ltd. announced plans to resurrect the platelet activating factor antagonist for the prophylaxis of neurological and renal complications in patients undergoing cardiac surgery.
"There is evidence that a variety of inflammatory mediators, including platelet-activating factor (PAF), may contribute to neuronal injury," said Chris Jordan, DevCo portfolio management director. Armed with this information, DevCo (Guildford, U.K.), a virtual biotech company with a neuroscience focus, is hypothesizing that lexipafant might have a future as a therapy for cognitive dysfunction associated with reperfusion injury following cardiac and renal surgery. ...